Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due ...
Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...
Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...
Axsome Therapeutics (AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05 in the ...
Revised guidelines for amyloid and tau positron emission tomography for Alzheimer’s disease and dementia state these tests ...
A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
All 16 of Indiana’s designated senior care organizations — known as Area Agencies on Aging — are now required to have a ...
There is a potential link between Alzheimer's disease and the herpes simplex virus-1 (HSV-1), which is a common cause for ...